The GNAS1 T393C polymorphism is associated with disease progression and survival in chronic lymphocytic leukemia

Clinical Cancer Research

Volumn 12, Issue 19, 2006, Pages 5686-5692

  Frey, Ulrich H ^a   Nückel, Holger ^a   Sellmann, Ludger ^a   Siemer, Dörte ^a   Küppers, Ralf ^a   Dürig, Jan ^a   Dührsen, Ulrich ^a   Siffert, Winfried ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN;

ADULT; AGED; ALPHA CHAIN; ARTICLE; B CELL LEUKEMIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; FEMALE; GENOTYPE; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; HUMANS; LEUKEMIA, B-CELL, CHRONIC; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 33750301162     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0288     Document Type: Article

References (40)

1. Stevenson FK, Caligaris-Cappio F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood 2004;103:4389-95.
2. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352:804-15.
3. Caligaris-Cappio F, Gottardi D, Alfarano A, et al. The nature of the B lymphocyte in B-chronic lymphocytic leukemia. Blood Cells Mol Dis 1993;19:601-13.
4. Binet JL. Prognostic factors in chronic lymphocytic leukaemia. Haematologica 1999:84 Suppl EHA-4:96-7.
5. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-6.
6. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated IgV(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848-54.
7. Del PG, Maurillo L, Venditti A, et al. Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood 2001;98:2633-9.
8. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001;194:1639-47.
9. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003;348:1764-75.
10. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004;351:893-901.
11. Nuckel H, Frey UH, Durig J, Duhrsen U, Siffert W. Methylenetetrahydrofolate reductase (MTHFR) gene 677C>T and 1298A>C polymorphisms are associated with differential apoptosis of leukemic B cells in vitro and disease progression in chronic lymphocytic leukemia. Leukemia 2004;18:1816-23.
12. Frey UH, Eisenhardt A, Lummen G, et al. The T393C polymorphism of the G α s gene (GNAS1) is a novel prognostic marker in bladder cancer. Cancer Epidemiol Biomarkers Prev 2005;14:871-7.
13. Frey UH, Alakus H, Wohlschlaeger J, et al. GNAS1 T393C polymorphism and survival in patients with sporadic colorectal cancer. Clin Cancer Res 2005;11:5071-7.
14. Frey UH, Lummen G, Jager T, et al. The GNAS1 T393C polymorphism predicts survival in patients with clear cell renal cell carcinoma. Clin Cancer Res 2006;12:759-63.
15. Myklebust JH, Josefsen D, Blomhoff HK, et al. Activation of the cAMP signaling pathway increases apoptosis in human B-precursor cells and is associated with downregulation of Mcl-1 expression. J Cell Physiol 1999;180:71-80.
16. 2-adrenergic receptor to different G proteins by protein kinase A. Nature 1997;390:88-91.
17. Krumins AM, Barber R. Examination of the effects of increasing Gs protein on β2-adrenergic receptor, Gs, and adenylyl cyclase interactions. Biochem Pharmacol 1997;54:61-72.
18. Yang X, Lee FY, Sr., Wand GS. Increased expression of Gs(α) enhances activation of the adenylyl cyclase signal transduction cascade. Mol Endocrinol 1997;11:1053-61.
19. Durig J, Naschar M, Schmucker U, et al. CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia. Leukemia 2002;16:30-5.
20. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990-7.
21. 3 subunit 825T allele and its association with obesity in Caucasian, Chinese, and Black African individuals. J Am Soc Nephrol 1999;10:1921-30.
22. Schroers R, Pukrop T, Durig J, et al. B-cell chronic lymphocytic leukemia with aberrant CD8 expression: genetic and immunophenotypic analysis of prognostic factors. Leuk Lymphoma 2004;45:1677-81.
23. Kuppers R. Molecular single-cell PCR analysis of rearranged immunoglobulin genes as a tool to determine the clonal composition of normal and malignant human B cells. Methods Mol Biol 2004;271:225-38.
24. Braeuninger A, Kuppers R, Strickler JG, et al. Hodgkin and Reed-Sternberg cells in lymphocyte predomi-nant Hodgkin disease represent clonal populations of germinal center-derived tumor B cells. Proc Natl Acad Sci U S A 1997;94:9337-42.
25. Pekova S, Baran-Marszak F, Schwarz J, Matoska V. Mutated or non-mutated? Which database to choose when determining the IgVH hypermutation status in chronic lymphocytic leukemia? Haematologica 2006;91:ELT01.
26. Cox DR, McCullagh P. Some aspects of analysis of covariance. Biometrics 1982;38:541-61.
27. Maloum K, Davi F, Merle-Beral H, et al. Expression of unmutated VH genes is a detrimental prognostic factor in chronic lymphocytic leukemia. Blood 2000;96:377-9.
28. Krober A, Seiler T, Benner A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002;100:1410-6.
29. Schroers R, Griesinger F, Trumper L, et al. Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia. Leukemia 2005;19:750-8.
30. Hamblin TJ. Predicting Progression-ZAP-70 in CLL. N Engl J Med 2004;351:856-7.
31. Ibrahim S, Keating M, Do KA, et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 2001;98:181-6.
32. Deaglio S, Capobianco A, Bergui L, et al. CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. Blood 2003;102:2146-55.
33. Hamblin TJ, Orchard JA, Gardiner A, et al. Immunoglobulin V genes and CD38 expression in CLL. Blood 2000;95:2455-7.
34. Yuille M, Condie A, Hudson C, et al. Relationship between glutathione S-transferase M1, T1, and P1 polymorphisms and chronic lymphocytic leukemia. Blood 2002;99:4216-8.
35. Yang W, White B, Spicer EK, Weinstein BL, Hildebrandt JD. Complex haplotype structure of the human GNAS gene identifies a recombination hotspot centered on a single nucleotide polymorphism widely used in association studies. Pharmacogenetics 2004;14:741-7.
36. Srivastava RK, Srivastava AR, Cho-Chung YS, Longo DL. Synergistic effects of retinoic acid and 8-CI-cAMP on apoptosis require caspase-3 activation in human ovarian cancer cells. Oncogene 1999;18:1755-63.
37. Yan L, Herrmann V, Hofer JK, Insel PA. β-Adrenergic receptor/cAMP-mediated signaling and apoptosis of S49 lymphoma cells. Am J Physiol Cell Physiol 2000;279:C1665-74.
38. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005;23:630-9.
39. Cheson BD. Hematologic malignancies: new devel opments and future treatments. Semin Oncol 2002;29:33-45.
40. Pahler JC, Ruiz S, Niemer I, et al. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia. Clin Cancer Res 2003;9:4570-7.